CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 137 filers reported holding CRINETICS PHARMACEUTICALS IN in Q2 2023. The put-call ratio across all filers is 19.18 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $7,834,519 | +12.2% | 434,768 | 0.0% | 0.13% | +3.1% |
| Q1 2023 | $6,982,374 | +89.5% | 434,768 | +80.3% | 0.13% | +132.7% |
| Q1 2021 | $3,685,000 | -34.7% | 241,140 | -39.7% | 0.06% | -36.8% |
| Q4 2020 | $5,644,000 | -73.3% | 400,000 | -70.3% | 0.09% | -78.9% |
| Q3 2020 | $21,107,000 | -10.6% | 1,347,000 | 0.0% | 0.41% | -19.5% |
| Q2 2020 | $23,599,000 | +69.5% | 1,347,000 | +42.2% | 0.51% | +13.7% |
| Q1 2020 | $13,921,000 | -41.4% | 947,000 | 0.0% | 0.45% | -32.6% |
| Q4 2019 | $23,760,000 | +66.8% | 947,000 | 0.0% | 0.67% | +42.0% |
| Q3 2019 | $14,243,000 | -29.1% | 947,000 | +17.8% | 0.47% | -22.9% |
| Q2 2019 | $20,096,000 | +129.9% | 803,839 | +109.3% | 0.61% | +103.0% |
| Q1 2019 | $8,740,000 | +136.5% | 384,000 | +211.6% | 0.30% | +83.5% |
| Q4 2018 | $3,696,000 | +4.7% | 123,225 | 0.0% | 0.16% | +26.2% |
| Q3 2018 | $3,530,000 | – | 123,225 | – | 0.13% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LLC | 623,819 | $11,336,501 | 9.41% |
| Finepoint Capital LP | 822,745 | $15,056 | 4.87% |
| Bain Capital Life Sciences Investors, LLC | 2,305,558 | $42,192 | 4.72% |
| Opaleye Management Inc. | 732,000 | $13,395,600 | 4.66% |
| 5AM Venture Management, LLC | 862,286 | $15,779,834 | 4.24% |
| SPHERA FUNDS MANAGEMENT LTD. | 671,644 | $12,291,085 | 2.64% |
| First Light Asset Management, LLC | 1,329,313 | $24,326,428 | 2.26% |
| BRAIDWELL LP | 3,469,674 | $63,495,034 | 2.13% |
| BVF INC/IL | 2,736,613 | $50,080,018 | 2.11% |
| Perceptive Advisors | 4,039,276 | $73,918,751 | 2.08% |